Altamira Therapeutics Ltd.

Equities

CYTO

BMG0360L1349

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
1.6 ^USD	+11.11%		+13.15%	-54.02%

Apr. 24	Altamira Therapeutics Ltd. Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal	CI
Apr. 10	Transcript : Altamira Therapeutics Ltd., 2023 Earnings Call, Apr 10, 2024

Altamira Therapeutics Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023

September 12, 2023 at 07:30 am EDT

Altamira Therapeutics Ltd. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was CHF 0.105469 million compared to CHF 0.290798 million a year ago. Net loss was CHF 5.42 million compared to CHF 8.24 million a year ago.

Latest news about Altamira Therapeutics Ltd.

Altamira Therapeutics Ltd. Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal	Apr. 24	CI
Transcript : Altamira Therapeutics Ltd., 2023 Earnings Call, Apr 10, 2024	Apr. 10
Altamira Therapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 10	CI
Sector Update: Health Care Stocks Decline Late Afternoon	Mar. 25	MT
Top Midday Gainers	Mar. 25	MT
Sector Update: Health Care Stocks Softer in Afternoon Trading	Mar. 25	MT
Altamira, Univercells Partner to Test mRNA Vaccine Delivery; Shares Surge	Mar. 25	MT
Altamira Therapeutics Ltd. Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines	Mar. 25	CI
Altamira Therapeutics? Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal	Feb. 07	CI
Altamira Files Second Provisional Patent Application in Cancer Treatment; Shares Rise	Jan. 24	MT
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment	Jan. 24	CI
Altamira Therapeutics Back in Compliance with Nasdaq Minimum Bid Price Rules	Dec. 29	MT
Transcript : Altamira Therapeutics Ltd. - Special Call	Dec. 11
Altamira Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders Equity Requirement	Nov. 29	MT
An unknown private equity investor acquired 51% stake in Altamira Medica AG from Altamira Therapeutics Ltd..	Nov. 20	CI
Sector Update: Health Care Stocks Slipping Late Afternoon	Nov. 17	MT
Top Midday Gainers	Nov. 17	MT
Altamira Therapeutics to Sell 51% of Bentrio Maker for $2.3 Million	Nov. 17	MT
An unknown private equity investor entered into a binding agreement to acquire 51% stake in Altamira Medica AG from Altamira Therapeutics Ltd. for CHF 2.04 million.	Nov. 16	CI
Altamira Therapeutics Ltd. Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic Rhinitis	23-09-14	CI
Transcript : Altamira Therapeutics Ltd., H1 2023 Earnings Call, Sep 12, 2023	23-09-12
Altamira Therapeutics Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-12	CI
Altamira Therapeutics Collaborating With Pharma Nordic to Market, Distribute Bentrio Nasal Spray in Scandinavia	23-07-20	MT
Altamira Therapeutics, Heqet Therapeutics Enter Into Collaboration for OligoPhore Platform	23-07-05	MT
Altamira Therapeutics Receives Non-Compliance Notice From Nasdaq	23-06-30	MT

Chart Altamira Therapeutics Ltd.

Duration

Period

More charts

Company Profile

Altamira Therapeutics Ltd. is a Bermuda-based company engaged in developing ribonucleic acid (RNA)-based therapeutics for extrahepatic targets (OligoPhore/SemaPhore delivery platforms). The Company has two flagship short interfering (siRNA) programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. The delivery platform is also suited for messenger RNA (mRNA) and other types of RNA therapeutics and is focused to be leveraged via out-licensing to pharma or biotech companies. The therapeutic objective for AM-401 is to slow down KRAS driven tumor cell growth and proliferation or to stop it altogether by delivering siRNA specifically inside tumor cells for gene knock down. AM-411 is a polyplex nanoparticle delivering siRNA to inflamed tissues to target the NF-kB signaling pathway, a critical regulator of immune and inflammatory responses. Like AM-401, the drug product is based on its OligoPhore technology.

Sector

Biotechnology & Medical Research

Calendar

2024-08-14 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ALTAMIRA THERAPEUTICS LTD.	-54.02%	3.79M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs